Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-209-1 | CAS number: 68412-54-4 1 - 2.5 moles ethoxylated
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Dermal absorption
Administrative data
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Well documented, meets generally accepted scientific principles, acceptable for assessment
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- In vitro percutaneous absorption of nonylphenol (NP) and nonylphenol ethoxylates (NPE-4 and NPE-9) in isolated perfused skin
- Author:
- Monteiro-Riviere NA et al.
- Year:
- 2 003
- Bibliographic source:
- J. Cut. Ocul. Tox. 22(1):1-11
Materials and methods
- Principles of method if other than guideline:
- The isolated perfused porcine skin flap (IPPSF), created on the porcine ventral abdomen, was used in this study. Two single-pedicle axial pattern skin flaps, each lateral to the ventral midline on the pig abdomen, were created during stage 1 and harvested during stage 2 surgery. The flaps were cannulated, flushed to clear the vasculature of blood, and transferred to a perfusion chamber. The flaps were perfused for 1 h prior to dosing, during which arterial and venous samples were collected to determine glucose utilization and zero-time perfusate samples for flux determinations. A stomahesive template was secured to the flap with skin-bond. The skin flap was returned to the chamber and dosed with radiolabeled test substance and after the perfusion was resumed. Perfusate samples were later collected and analyzed for glucose and radioactivity.The remaining venous efflux was collected for 14C determination. The flap and cradle were removed from the flap chamber and rinsed for recovery and the dose area was washed. The tape strips were placed in vials containing ethyl acetate for estimation of stratum corneum penetration.
Flow-through diffusion cell system (PSFT): Pig skin was dermatomed and circular sections were mounted epidermal side up in diffusion cell blocks. Skin was equilibrated in the diffusion cell chambers prior to dosing. A constant perfusate flow rate was maintained during the study. Treatments were dosed with test substance to a nonoccluded areal and perfusate was collected during the study. At the completion of the study tape strips were collected for estimation of stratum corneum penetration. The upper half of the chamber was rinsed and the wash collected for mass balance determination. The remaining skin section was divided into dosing site and peripheral tissue. Perfusate and all tissue samples were then analyzed for total 14C determination - GLP compliance:
- not specified
Test material
- Reference substance name:
- NP
- IUPAC Name:
- NP
- Details on test material:
- - Name of test material (as cited in study report): Nonylphenol (NP)
- Substance type: Nonionic surfactant
- Other: Specific activity 2.214 mCi/mmol
Constituent 1
- Radiolabelling:
- yes
Test animals
- Species:
- pig
- Strain:
- other: PSFT study: Yorkshire pig
- Sex:
- not specified
Administration / exposure
- Type of coverage:
- other: IPPSF study: occlusive; PSFT study: nonocclusive
- Vehicle:
- other: PEG-400
- Duration of exposure:
- IPPSF: 8 h
PSFT: 10 h - Doses:
- 1%
- No. of animals per group:
- 4 replicates
- Control animals:
- no
- Details on study design:
- DOSE PREPARATION
- Method for preparation of dose suspensions:
IPPSF: 100 µL of 1% radiolabeled test substance was mixed with 79% aqueous PEG-400
PSFT: 10 µL of 1% radiolabeled test substance was mixed with PEG-400
APPLICATION OF DOSE: 1%
VEHICLE
- Justification for use and choice of vehicle (if other than water): The 1% aqueous PEG-400 solutions were selected for use in these studies since the previous work had indicated that absorption was not altered by vehicle (PEG-400 vs. water) or by concentration (0.1, 1.0, or 10%)
- Concentration (if solution):
IPPSF: 79%
PSFT: Not reported
TEST SITE
- Preparation of test site:
IPPSF:The flaps were cannulated, flushed with heparinized saline to clear the vasculature of blood, and each transferred to a perfusion chamber. The flaps were perfused for 1 h prior to dosing, during which 1.0-ml arterial and 3.0-ml venous samples were collected at 30 and 60 min to determine glucose utilization and zero-time perfusate samples for nonylphenol flux determinations. Upon confirming flap viability, the perfusion was interrupted and each flap was removed from the chamber.
PSFT: Pig skin was dermatomed using a padgett dermatome (Kansas City, MO). Circular sections were mounted epidermal side up in the teflon diffusion cell blocks. Skin was equilibrated in the diffusion cell chambers for 30 min prior to dosing.
- Area of exposure:
IPPSF: 5.0 cm2
PSFT: 0.32 cm2
- Type of cover / wrap if used:
IPPSF: A stomahesive (ConvaTec, Princeton NJ) template secured with skin-bond (Smith & Nephew, Inc., Largo, FL).
SITE PROTECTION / USE OF RESTRAINERS FOR PREVENTING INGESTION: Not applicable
REMOVAL OF TEST SUBSTANCE
- Removal of protecting device:
IPPSF: The flap and cradle were removed from the flap chamber and rinsed for recovery.
- Washing procedures and type of cleansing agent:
IPPSF: The dose area was swabbed with a mild soap solution to remove nonpenetrated chemical and tape stripped 12 times
PSFT: The application site was swabbed with soapy solution
- Time after start of exposure: After completion of the studies
SAMPLE COLLECTION
- Collection of blood:
IPPSF: While the flaps were perfused for 1 h prior to dosing, 1.0 ml arterial and 3.0 ml venous samples were collected at 30 and 60 min
- Preparation of samples:
IPPSF: Perfusate samples that were collected during the study were analyzed for glucose and radioactivity. Remaining venous efflux was thoroughly stirred and a 3.0 ml sample collected for 14C determination. The tape strips were placed in vials containing ethyl acetate for estimation of stratum corneum penetration. The remaining tissue from the dose site and the entire flap were completely digested in soluene-350.
PSFT: The cellophane tape strips were collected for estimation of stratum corneum penetration.The upper half of the chamber was rinsed and the wash collected for mass balance determination. The remaining skin section was divided into dosing site and peripheral tissue. Perfusate and all tissue samples were combusted in an automated tissue oxidizer.
ANALYSIS
- Method type(s) for identification: Liquid scintillation counting (Packard Chemical Co., Downers Grove, IL) - Details on in vitro test system (if applicable):
- SKIN PREPARATION
- Type of skin: From pig
- Thickness of skin (in mm): 0.5
- Justification of species, anatomical site and preparative technique:The studies were conducted in an ex vivo perfused porcine skin model that has been shown to predict human exposure because of its intact vasculature, as well as anatomical and physiological similarities to human skin
PRINCIPLES OF ASSAY
- Diffusion cell: Teflon diffusion cell blocks
- Receptor fluid: Krebs–ringer bicarbonate buffer with added glucose and bovine serum albumin
- Flow-through system: Yes (flow rate: 4.0 ml/h)
- Test temperature: 37 degree C
- Humidity: 55-65%
- Occlusion: Nonoccluded
Results and discussion
- Signs and symptoms of toxicity:
- not examined
- Dermal irritation:
- not examined
- Absorption in different matrices:
- - Absorption:
IPPSF: (%) 0.10 ± 0.04; (µg) 0.96 ± 0.37
PSFT: (%) 0.14 ± 0.02
- Surface swabs:
IPPSF: (%) 77.61 ± 2.68; (µg) 735.60 ± 23.90
PSFT: (%) 78.40 ± 5.00
- Stratum corneum (in vitro test system):
IPPSF: (%) 0.90 ± 0.33; (µg) 8.56 ± 3.07
PSFT: (%) 2.21 ± 0.39
- Dosed skin:
IPPSF: (%) 0.32 ± 0.04; (µg) 2.99 ± 0.42
PSFT: (%) 0.41 ± 0.13
- Penetration:
IPPSF: (%) 0.75 ± 0.21; (µg) 7.16 ± 2.03
PSFT: (%) 2.76 ± 0.51 - Total recovery:
- - Total recovery:
IPPSF: (%) 84.38 ± 1.52; (µg) 799.80 ± 12.70
PSFT: (%) 91.76 ± 4.92
- Conversion factor human vs. animal skin:
- Not determined
Any other information on results incl. tables
The amount of applied chemical that penetrates the stratum corneum and skin in the IPPSF is considered to be the maximum estimate in humans that ultimately could be absorbed since it assumes no loss due to exfoliation of the stratum corneum.
Comparison of the IPPSF results with those from previous studies indicates that the amounts absorbed into the perfusate are remarkably similar, although a smaller percentage of the applied dose penetrated into the IPPSF.
The mean perfusate flux in the IPPSF and PSFT studies are presented in Figure 2 and 3.
Applicant's summary and conclusion
- Conclusions:
- Under the test conditions, nonylphenol was considered to be minimally absorbed in the IPPSF model and the potential systematic exposure from skin contact in humans is considerably less than 1%. According to the author this result confirms the estimates from previous in vitro studies.
- Executive summary:
A study was conducted to evaluate the absorption of the test substance in isolated perfused skin (IPPSF) and to assess the percutaneous absorption to a previous published in vitro porcine study in a flow-through diffusion cell system (PSFT).
The isolated perfused porcine skin flap (IPPSF), created on the porcine ventral abdomen, was used in this study. Two single-pedicle axial pattern skin flaps, each lateral to the ventral midline on the pig abdomen, were created during stage 1 and harvested during stage 2 surgery. The flaps were cannulated, flushed to clear the vasculature of blood, and transferred to a perfusion chamber. The flaps were perfused for 1 h prior to dosing, during which arterial and venous samples were collected to determine glucose utilization and zero-time perfusate samples for flux determinations. A stomahesive template was secured to the flap with skin-bond. The skin flap was returned to the chamber and dosed with radiolabeled test substance and after the perfusion was resumed. Perfusate samples were later collected and analyzed for glucose and radioactivity.The remaining venous efflux was collected for 14C determination. The flap and cradle were removed from the flap chamber and rinsed for recovery and the dose area was washed. The tape strips were placed in vials containing ethyl acetate for estimation of stratum corneum penetration.
Flow-through diffusion cell system (PSFT): Pig skin was dermatomed and circular sections were mounted epidermal side up in diffusion cell blocks. Skin was equilibrated in the diffusion cell chambers prior to dosing. A constant perfusate flow rate was maintained during the study. Treatments were dosed with test substance to a nonoccluded areal and perfusate was collected during the study. At the completion of the study tape strips were collected for estimation of stratum corneum penetration. The upper half of the chamber was rinsed and the wash collected for mass balance determination. The remaining skin section was divided into dosing site and peripheral tissue. Perfusate and all tissue samples were then analyzed for total 14C determination.
The amount of applied chemical that penetrates the stratum corneum and skin in the IPPSF is considered to be the maximum estimate in humans that ultimately could be absorbed since it assumes no loss due to exfoliation of the stratum corneum.
Comparison of the IPPSF results with those from previous studies indicates that the amounts absorbed into the perfusate are remarkably similar, although a smaller percentage of the applied dose penetrated into the IPPSF.
Under the study conditions, the test substance was considered to be minimally absorbed in the IPPSF model and the potential systematic exposure from skin contact in humans is considerably less than 1%. According to the author this result confirms the estimates from previous in vitro studies.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.